Cannabis, Cannabinoids, and Cerebral Metabolism: Potential Applications in Stroke and Disorders of the Central Nervous System

Current Cardiology Reports

Volumn 17, Issue 9, 2015, Pages

  Latorre, Julius Gene S ^a   Schmidt, Elena B ^b  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Cannabinoid; Cannabis; Endocannabinoids; Ischemia; Neuroprotection; Stroke

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABIS; DRONABINOL; ENDOCANNABINOID; CANNABINOID; CANNABINOID RECEPTOR AFFECTING AGENT; MEDICAL CANNABIS; NEUROPROTECTIVE AGENT;

ADVERSE OUTCOME; BRAIN METABOLISM; CANNABIS USE; CARDIOVASCULAR EFFECT; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; DRUG MECHANISM; HEALTH HAZARD; HUMAN; LIPOGENESIS; NEUROPROTECTION; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; REVIEW; CENTRAL NERVOUS SYSTEM DISEASES; PHYTOTHERAPY; STROKE; TREATMENT OUTCOME;

CANNABINOID RECEPTOR MODULATORS; CANNABINOIDS; CANNABIS; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; MEDICAL MARIJUANA; NEUROPROTECTIVE AGENTS; PHYTOTHERAPY; STROKE; TREATMENT OUTCOME;

EID: 84938559911     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-015-0627-3     Document Type: Review

References (46)

1. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147 Suppl 1:S163–71. This paper provides a historical perspective on the discovery of cannabinoids, cannabinoid pharmacology, and its potential application in health and disease.
2. Mechoulam R. Looking back at cannabis research. Curr Pharm Des. 2000;6(13):1313–22.
3. El-Alfy AT et al. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol Biochem Behav. 2010;95(4):434–42.
4. Devane WA et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946–9.
5. Mechoulam R et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50(1):83–90.
6. Seely KA et al. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39(2):234–43.
7. Maccarrone M et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci. 2015;36(5):277–96. This review provides an overview of the discovery of the endocannabinoid system (ECS). In addition, it reviews the potential therapeutic applications of ECS as well as emerging challenges and gaps in knowledge in cannabinoid research.
8. Pertwee RG et al. International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol Rev. 2010;62(4):588–631.
9. Matsuda LA et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561–4.
10. Stanley C, O’Sullivan SE. Vascular targets for cannabinoids: animal and human studies. Br J Pharmacol. 2014;171(6):1361–78. This review provides an excellent summary of animal and human in vitro studies on sites of action and vascular targets for cannabinoids and similar compounds.
11. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61–5.
12. Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol. 2010;160(3):467–79.
13. Kim SH et al. Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity. Mol Pharmacol. 2006;69(3):691–6.
14. Pacher P, Hasko G. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol. 2008;153(2):252–62. This review summarizes the role of endocannabinoids and cannabinoid receptors in various forms of ischemia-reperfusion injury and preconditioning.
15. Aguado T et al. The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis. J Biol Chem. 2007;282(33):23892–8.
16. van der Stelt M, Di Marzo V. Cannabinoid receptors and their role in neuroprotection. Neuromolec Med. 2005;7(1–2):37–50.
17. Ralevic V et al. Cannabinoid modulation of sensory neurotransmission via cannabinoid and vanilloid receptors: roles in regulation of cardiovascular function. Life Sci. 2002;71(22):2577–94.
18. Capettini LS et al. Update on the role of cannabinoid receptors after ischemic stroke. Mediat Inflamm. 2012;2012:824093. This paper provides an updated review of the current available evidence on the neuroprotective properties of cannabinoids after ischemic stroke in humans and animal models.
19. Freedland CS et al. Dose-dependent effects of Delta9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat. Synapse. 2002;45(2):134–42.
20. Whitlow CT, Freedland CS, Porrino LJ. Functional consequences of the repeated administration of Delta9-tetrahydrocannabinol in the rat. Drug Alcohol Depend. 2003;71(2):169–77.
21. Stanley CP, Hind WH, O’Sullivan SE. Is the cardiovascular system a therapeutic target for cannabidiol? Br J Clin Pharmacol. 2013;75(2):313–22.
22. Hillard CJ. Role of cannabinoids and endocannabinoids in cerebral ischemia. Curr Pharm Des. 2008;14(23):2347–61. This paper provides the hypothesized mechanisms involved in the neuroprotective effects of cannabinoid receptor activation or inhibition.
23. Sun S et al. Pharmacologically induced hypothermia with cannabinoid receptor agonist WIN55, 212–2 after cardiopulmonary resuscitation. Crit Care Med. 2010;38(12):2282–6.
24. Ma L et al. Improved cardiac and neurologic outcomes with postresuscitation infusion of cannabinoid receptor agonist WIN55, 212–2 depend on hypothermia in a rat model of cardiac arrest. Crit Care Med. 2014;42(1):e42–8.
25. Fernandez-Lopez D et al. Cannabinoids: well-suited candidates for the treatment of perinatal brain injury. Brain Sci. 2013;3(3):1043–59.
26. Murikinati S et al. Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J. 2010;24(3):788–98.
27. Fernandez-Lopez D et al. Reduced infarct size and accumulation of microglia in rats treated with WIN 55,212-2 after neonatal stroke. Neuroscience. 2012;207:307–15.
28. Suzuki N et al. Cerebroprotective effects of TAK-937, a cannabinoid receptor agonist, on ischemic brain damage in middle cerebral artery occluded rats and non-human primates. Brain Res. 2012;1430:93–100.
29. Sommer C et al. Neuroprotective cannabinoid receptor antagonist SR141716A prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra. Acta Neuropathol. 2006;112(3):277–86.
30. Zhang M et al. Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury. Neuroscience. 2008;152(3):753–60.
31. Zarruk JG et al. Cannabinoid type 2 receptor activation downregulates stroke-induced classic and alternative brain macrophage/microglial activation concomitant to neuroprotection. Stroke. 2012;43(1):211–9.
32. Molina-Holgado F et al. CB2 cannabinoid receptors promote mouse neural stem cell proliferation. Eur J Neurosci. 2007;25(3):629–34.
33. Downer EJ. High hopes for CB(2) receptors in neurogenesis. Br J Pharmacol. 2014;171(6):1345–6.
34. Palazuelos J et al. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J. 2006;20(13):2405–7.
35. Maas AI et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol. 2006;5(1):38–45.
36. Wolff V et al. Cannabis use, ischemic stroke, and multifocal intracranial vasoconstriction: a prospective study in 48 consecutive young patients. Stroke. 2011;42(6):1778–80.
37. Wolff V et al. High frequency of intracranial arterial stenosis and cannabis use in ischaemic stroke in the young. Cerebrovasc Dis. 2014;37(6):438–43.
38. Seely KA et al. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv. 2011;11(1):36–51.
39. Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci. 2012;367(1607):3353–63.
40. Devinsky O et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55(6):791–802.
41. Bergamaschi MM et al. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf. 2011;6(4):237–49.
42. Ignatowska-Jankowska BM et al. In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. Br J Pharmacol. 2014;171(6):1392–407.
43. Jesudason D, Wittert G. Endocannabinoid system in food intake and metabolic regulation. Curr Opin Lipidol. 2008;19(4):344–8.
44. Pavon FJ et al. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. J Neuroendocrinol. 2008;20 Suppl 1:116–23.
45. Addy C et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab. 2008;7(1):68–78.
46. Zuba D, Byrska B, Maciow M. Comparison of “herbal highs” composition. Anal Bioanal Chem. 2011;400(1):119–26.